What is the role of matrix metalloproteinase‐2 in placenta percreta?

Koçarslan, Sezen; Incebiyik, Adnan; Güldür, Muhammet Emin; Ekinci, Turan; Özardalı, Hasan İlyas

doi:10.1111/jog.12667

Cited by 23 publications

(20 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Matrix metalloproteinase (MMP) is a group of enzymes that play an important role in the penetration of trophoblast cells by degrading the extracellular matrix [ 38 ]. Specifically, the gelatinases MMP-2 and MMP-9 are found in high concentrations in the placenta [ 39 ]. There is conflicting evidence about their significance in PAS.…”

Section: Molecular Biologymentioning

confidence: 99%

Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers

et al. 2018

View full text Add to dashboard Cite

Background. Placenta accreta spectrum (PAS) is a condition of abnormal placental invasion encompassing placenta accreta, increta, and percreta and is a major cause of severe maternal morbidity and mortality. The diagnosis of a PAS is made on the basis of histopathologic examination and characterised by an absence of decidua and chorionic villi are seen to directly adjacent to myometrial fibres. The underlying molecular biology of PAS is a complex process that requires further research; for ease, we have divided these processes into angiogenesis, proliferation, and inflammation/invasion. A number of diagnostic serum biomarkers have been investigated in PAS, including human chorionic gonadotropin (HCG), pregnancy-associated plasma protein-A (PAPP-A), and alpha-fetoprotein (AFP). They have shown variable reliability and variability of measurement depending on gestational age at sampling. At present, a sensitive serum biomarker for invasive placentation remains elusive. In summary, there are a limited number of studies that have contributed to our understanding of the molecular biology of PAS, and additional biomarkers are needed to aid diagnosis and disease stratification.

show abstract

Section: Molecular Biologymentioning

confidence: 99%

Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Several studies reported possible molecular or genetic changes in PAS compared to normal controls, such as MMP2 might be increased in placenta percreta [23], or MicroRNA-34a might be decreased in placenta accreta [29], but they only compared the genetic changes between cases and controls in groups. In this study, the CTSV staining pattern in EVT was compared between the adherent site and the non-adherent site within identical cases, and the pattern was found to differ according to the adhesion status where EVT was located.…”

Section: Discussionmentioning

confidence: 99%

“…Thus, only the results by immunohistochemical analysis could be recognized as the solid findings in this study. During placental development, proteases such as MMPs, plasminogen activators, or cathepsins have been reported to play important roles in the invasion of trophoblast by degrading extracellular matrix components and facilitating trophoblast penetration into the decidua [23][24][25].…”

Section: Discussionmentioning

confidence: 99%

Possible Association between Cathepsin V and the Development of Placenta Accreta Spectrum Disorders

Matsukawa

Sato

Kotani

et al. 2019

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background/Aims: The study aimed to evaluate molecular changes related to trophoblast adhesion in placenta accreta spectrum (PAS) disorders. Methods: A retrospective analysis of 10 PAS cases in which both the trophoblast adherent site and the non-adherent site were identified was performed in April 2010 and March 2013. Microarray analysis and reverse transcription polymerase chain reaction (RT-PCR) analyses were performed to extract upregulated genes in the adherent site. Gene expression changes were examined by immunohistochemistry. Results: Microarray analysis showed that 157 transcripts were > 3-fold upregulated, including the following: a disintegrin and metalloproteinase-28 (ADAM28), 3.10-fold; cathepsin V (CTSV), 3.73-fold; cathepsin S (CTSS), 3.46-fold; and matrix metalloproteinase-19 (MMP19), 3.41-fold. RT-PCR showed relatively high mRNA expressions. On immunohistochemistry, extravillous trophoblast (EVT) at the non-adherent site showed weak or no CTSV expression, whereas EVT that invaded myometrium at the adherent site showed strong expression (histological score, median [min-max], 115.6 [37.6–153.6] vs. 184.8 [56.4–222.8], p < 0.05). MMP19 showed moderate staining, with no difference between the adherent and non-adherent sites. ADAM28 and CTSS showed weak or no staining. Discussion: This limited study suggests that CTSV may be involved in the pathogenesis of PAS.

show abstract

“…For all the study subjects, immunohistochemical evaluation was made of 5 fields selected at random from the sections of placental tissue at x400 original magnification.The immunohistochemical staining of osteopontin was evaluated with a semi-quantitative scoring system in which cytoplasmic staining intensity was categorised as negative (0), weakly positive (1+), moderately positive (2+) or strongly positive (3+). A result of > 50% of the cells with strong staining was determined as strongly positive (3+), < 25% as weakly positive (1+) and 25-50% as moderately positive (2+) [13].…”

Section: Immunohistochemical Scoringmentioning

confidence: 99%

The role of osteopontin in the pathogenesis of placenta percreta

Özer

Yaylali²,

Koçarslan³

2018

Ginekol Pol

View full text Add to dashboard Cite

show abstract

What is the role of matrix metalloproteinase‐2 in placenta percreta?

Abstract: The stronger expression of the MMP-2 enzyme in the PP as compared to the normal placental tissue suggests that this enzyme may be an effective mediator in the pathogenesis of PP.

Cited by 23 publications

References 22 publications

Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers

Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers

Possible Association between Cathepsin V and the Development of Placenta Accreta Spectrum Disorders

The role of osteopontin in the pathogenesis of placenta percreta

Contact Info

Product

Resources

About